The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of ...
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
Morgan Stanley analyst Terence Flynn maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,185.00.
The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...
Hosted on MSN1d
UNAIDS Calls On Leaders At Davos To Commit To Rapid Global Access To Revolutionary New Long-Acting HIV MedicinesUNAIDS urges speed and compassion urging pharmaceutical companies to enable access to new, life-saving medicines DAVOS/GENEVA, 21 January 2025—Today, at the World Economic Forum’s annual meeting in ...
As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...
The drug has given promising results for the treatment of multiple myeloma, a rare form of blood cancer. The market for such ...
Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered ...
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback